According to a new report North America Meningococcal Vaccine Market, published by KBV research, the North America Meningococcal Vaccine Market would witness market growth of 7.8% CAGR during the forecast period (2020-2026).
The USA market dominated the North America Menactra Market by Country in 2019, and would continue to be a dominant market till 2026. The Canada market is exhibiting a CAGR of 5.4% during (2020 - 2026). Additionally, The Mexico market would witness a CAGR of 7.4% during (2020 - 2026).
The Quadrivalent market dominated the Canada Meningococcal Vaccine Market by Type in 2019, growing at a CAGR of 7.9 % during the forecast period. The Bivalent market is experiencing a CAGR of 8.3% during (2020 - 2026).
The Children (2 years & above) and Adults market dominated the Mexico Meningococcal Vaccine Market by Age Group in 2019, growing at a CAGR of 9.4 % during the forecast period. The Infants (0 to 2 years) market would showcase a CAGR of 12.1% during (2020 - 2026).
Full Report: https://www.kbvresearch.com/north-america-meningococcal-vaccine-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of GlaxoSmithKline PLC (GSK), Pfizer, Inc., Sanofi S.A., Walvax Biotechnology Co., Ltd., Bio-Manguinhos (Oswaldo Cruz Foundation), Bio-Med Pvt. Ltd., Chongqing Zhifei Biological Products Co., Ltd., Hualan Biological Engineering, Inc., Incepta Pharmaceuticals Ltd. and Serum Institute of India Pvt. Ltd. (Poonawalla Investments & Industries Pvt. Ltd.)
By Brand
By Type
By Age Group
By Country
Companies Profiled
Unique Offerings from KBV Research
Unique Offerings 
